Ricardo Alonso-Zaldivar, AP
Trouble-prone medical products widely used to surgically repair women's pelvic problems need more stringent tests for safety and effectiveness, government advisers recommended Thursday. A panel of outside advisers to the Food and Drug Administration urged the FDA to reclassify plastic surgical mesh used to repair pelvic collapse. If the FDA agrees, manufacturers would be required to prove the safety and effectiveness of the products before they could continue to market them. However, the process could take several years.
Consumer groups want the agency to issue a recall now, but medical device manufacturers say mesh offers important advantages in the hands of a trained surgeon, and the rate of serious complications is low. An FDA review found problems that include pain, bleeding and infection, prompting the agency to warn patients and doctors. Some women have needed multiple surgeries to remove the mesh.
Safety concerns could prompt a shift back to traditional surgery with stitches to repair what is known as pelvic prolapse, a common condition affecting older women. In July, the FDA issued a mea culpa, saying it was mistaken in its initial assessment that safety issues with mesh for pelvic collapse were rare. The agency said 10 percent of women experienced erosion or exposure of the mesh within 12 months of their initial surgery. More than half of these women required follow-up surgery to remove the mesh. Some required two or three surgeries.
At the same time, the FDA said it saw no evidence that using mesh led to better outcomes than traditional surgery with stitches. "If they had done studies on this product in the first place, we wouldn't be in this situation," said Diana Zuckerman, president of the National Center for Women and Families, a consumer group for women's health issues.
The FDA also is reviewing the use of mesh to treat urinary incontinence, but there have been fewer complications among incontinence patients than among those who underwent surgery for pelvic collapse. The FDA is considering reclassifying the mesh products for pelvic collapse, an action that would require the manufacturers to submit evidence of safety and effectiveness in order to continue to market.